Wikidata entity: Q90693178
Quantities
| P2899 | minimum age | 18 |
| P1132 | number of participants | 508 |
| P6099 | clinical trial phase | ... | Q42824440 (phase II clinical trial) | phase II clinical trial |
| P582 | end time | ... | 2021-01-31 | ??? |
| P31 | instance of | ... | Q30612 (clinical trial) | clinical trial |
| P1813 | short name | Monolingualtext | CTII-nCoV | ??? |
| P580 | start time | ... | 2020-04-12 | ??? |
| P8363 | study type | ... | Q78089383 (interventional study) | interventional study |
| P1476 | title | Monolingualtext | A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years | ??? |
| P3098 | ClinicalTrials.gov ID | NCT04341389 |
Why not click here or view trends?
log id: 5676886